ASX Share rice
Wed 05 Aug 2020 - 11:27:pm (Sydney)

EX1 Share Price

EXOPHARM LIMITEDEX1Pharmaceuticals, Biotechnology & Life Sciences

EX1 Company Information


Exopharm Limited






31 Queen Street Melbourne VIC Australia 3000


61 3 9111 0026

Full Time Employees:


Company Founder, Technology Co-Founder, MD & Director:

Dr. Ian E. Dixon M.A.I.C.D., M.B.A., MBA, Ph.D.

COO & Technology Co-Founder:

Dr. Gregory Lichtfuss M.Sc.

Chief Commercial Officer:

Dr. Christopher Baldwin Ph.D.

Company Sec. & Director:

Ms. Sinead Teague L.L.B., M.Sc.

Company Overview:

Exopharm Limited, a biopharmaceutical company, focuses on developing and commercializing human therapeutics in Australia. The company is Plexaris and Exomere products, including non-clinical, pre-clinical, and clinical testing for other medical conditions, such as dry age-related macular degeneration and osteoarthritis. Exopharm Limited was founded in 2013 and is headquartered in Melbourne, Australia.

EX1 Share Price Information

Shares Issued:


Market Capitalisation:


Revenue (TTM):


Earnings per Share:


Operating Margin (TTM):


Return On Assets (TTM):


Return On Equity (TTM):


Quarterly Revenue Growth (YOY):


Gross Profit(TTM):


Diluted Earnings Per Share (TTM):


EX1 CashFlow Statement

CashFlow Date:




Change To Liabilities:


Total Cashflow From Investing Activities:


Net Income:


Total Cash From Operating Activities:




Capital Expenditures:


EX1 Income Statement

Income Date:


Income Before Tax:


Net Income:


Gross Profit:


Operating Income:


Other Operating Expenses:


Total Revenue:


Total Operating Expenses:


Cost Of Revenue:


EX1 Balance Sheet

Balance Sheet Date:


Intangible Assets:


Total Liabilities:


Total Stockholder Equity:


Other Current Liabilities:


Total Assets:


Common Stock:


Other Current Assets:


Retained Earnings:




Total Current Liabilities:


Property - Plant & Equipment:


Net Tangible Assets:


Total Current Assets:


Net Receivables:


Short-Term Investments:


Accounts Payable:


Non Currrent Assets (Other):


Short-Term Investments:


Non Current Liabilities Total:


EX1 Share Price History

EX1 News

24 Feb, 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
29 Jan, 2020
The first human dosing of PlexarisTM has occurred in Exopharm’s PLEXOVAL Study.
19 Dec, 2019
A leading developer of exosome therapies, Australia-based Exopharm Limited, supports the US Food & Drug Administration (FDA) in highlighting the health dangers of unapproved products peddled by clinics that are openly flouting the rules.
25 Oct, 2019
If you want to know who really controls Exopharm Limited (ASX:EX1), then you'll have to look at the makeup of its...